Eli Lilly and Company (NYSE:LLY – Get Free Report) shares rose 2.3% on Tuesday . The company traded as high as $920.28 and last traded at $918.90. 633,356 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 3,018,146 shares. The stock had previously closed at $898.40.
Analysts Set New Price Targets
LLY has been the topic of a number of research reports. Wells Fargo & Company raised their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Bank of America upped their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $979.29.
Get Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Trading Up 0.5 %
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, sell-side analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.
Institutional Trading of Eli Lilly and Company
Hedge funds have recently modified their holdings of the business. Capital Planning LLC bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in Eli Lilly and Company during the first quarter valued at $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company in the first quarter worth $8,896,000. HighPoint Advisor Group LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter worth $9,878,000. Finally, Leo Wealth LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $3,355,000. Institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- What to Know About Investing in Penny Stocks
- These 3 Stocks Are Screaming Oversold: Seize the Opportunity
- 3 Healthcare Dividend Stocks to Buy
- Stryker’s Acquisition Spree: Double-Digit Growth on the Horizon
- Transportation Stocks Investing
- Carnival Has Analysts Going Wild: Here’s Why
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.